Does the media refer more to UPB or RANI?

In the previous week, Rani Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for Rani Therapeutics and 2 mentions for Upstream Bio. Rani Therapeutics' average media sentiment score of 1.51 beat Upstream Bio's score of 0.60 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is RANI or CMPX more profitable?

Compass Therapeutics' return on equity of -38.71% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Compass Therapeutics N/A -38.71% -34.72%

Does the media prefer RANI or CMPX?

In the previous week, Compass Therapeutics had 13 more articles in the media than Rani Therapeutics. MarketBeat recorded 16 mentions for Compass Therapeutics and 3 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 1.51 beat Compass Therapeutics' score of 0.05 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Compass Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RANI or RCKT more profitable?

Rocket Pharmaceuticals' return on equity of -69.61% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Rocket Pharmaceuticals N/A -69.61% -58.63%

Does the media prefer RANI or RCKT?

In the previous week, Rani Therapeutics had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 3 mentions for Rani Therapeutics and 2 mentions for Rocket Pharmaceuticals. Rani Therapeutics' average media sentiment score of 1.51 beat Rocket Pharmaceuticals' score of 0.34 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rocket Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RANI or PRLD more profitable?

Prelude Therapeutics' return on equity of -118.24% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Prelude Therapeutics N/A -118.24% -66.12%

Does the media refer more to RANI or PRLD?

In the previous week, Rani Therapeutics had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Rani Therapeutics and 2 mentions for Prelude Therapeutics. Rani Therapeutics' average media sentiment score of 1.51 beat Prelude Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SVA or RANI?

Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 1,029.03%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has higher earnings & valuation, SVA or RANI?

Rani Therapeutics has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Rani Therapeutics $1.63M 58.90 -$29.67M -$0.41 N/A

Is SVA or RANI more profitable?

Sinovac Biotech's return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Rani Therapeutics N/A -206.46% -83.95%

Rani Therapeutics (RANI) Competitors

$0.78 -0.02 (-2.02%)

As of 03:56 PM Eastern

Compare

RANI vs. UPB, CMPX, RCKT, PRLD, and SVA

Should you buy Rani Therapeutics stock or one of its competitors? MarketBeat compares Rani Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rani Therapeutics include Upstream Bio (UPB), Compass Therapeutics (CMPX), Rocket Pharmaceuticals (RCKT), Prelude Therapeutics (PRLD), and Sinovac Biotech (SVA). These companies are all part of the "biotechnology" industry.

How does Rani Therapeutics compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

30.2% of Rani Therapeutics shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Upstream Bio presently has a consensus price target of $33.17, suggesting a potential upside of 340.58%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 1,029.03%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rani Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Rani Therapeutics	N/A	-206.46%	-83.95%

Rani Therapeutics has lower revenue, but higher earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$3.32M	123.32	-$143.44M	-$2.91	N/A
Rani Therapeutics	$1.63M	58.90	-$29.67M	-$0.41	N/A

Upstream Bio has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

In the previous week, Rani Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for Rani Therapeutics and 2 mentions for Upstream Bio. Rani Therapeutics' average media sentiment score of 1.51 beat Upstream Bio's score of 0.60 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Rani Therapeutics beats Upstream Bio on 10 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Compass Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Rani Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 1,029.03%. Compass Therapeutics has a consensus price target of $11.77, suggesting a potential upside of 438.64%. Given Rani Therapeutics' higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Compass Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Rani Therapeutics has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	58.90	-$29.67M	-$0.41	N/A
Compass Therapeutics	N/A	N/A	-$66.49M	-$0.40	N/A

In the previous week, Compass Therapeutics had 13 more articles in the media than Rani Therapeutics. MarketBeat recorded 16 mentions for Compass Therapeutics and 3 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 1.51 beat Compass Therapeutics' score of 0.05 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Compass Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Rani Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Compass Therapeutics' return on equity of -38.71% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Compass Therapeutics	N/A	-38.71%	-34.72%

Summary

Compass Therapeutics beats Rani Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Rocket Pharmaceuticals?

Rani Therapeutics (NASDAQ:RANI) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

In the previous week, Rani Therapeutics had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 3 mentions for Rani Therapeutics and 2 mentions for Rocket Pharmaceuticals. Rani Therapeutics' average media sentiment score of 1.51 beat Rocket Pharmaceuticals' score of 0.34 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rocket Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rani Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Rani Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 1,029.03%. Rocket Pharmaceuticals has a consensus target price of $8.71, suggesting a potential upside of 141.73%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Rani Therapeutics is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Rocket Pharmaceuticals' return on equity of -69.61% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Rani Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	58.90	-$29.67M	-$0.41	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Rani Therapeutics beats Rocket Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Rani Therapeutics compare to Prelude Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Rani Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 1,029.03%. Prelude Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 57.91%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Rani Therapeutics has higher earnings, but lower revenue than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	58.90	-$29.67M	-$0.41	N/A
Prelude Therapeutics	$12.14M	31.85	-$99.50M	-$1.00	N/A

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Prelude Therapeutics' return on equity of -118.24% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Prelude Therapeutics	N/A	-118.24%	-66.12%

Rani Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

In the previous week, Rani Therapeutics had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 3 mentions for Rani Therapeutics and 2 mentions for Prelude Therapeutics. Rani Therapeutics' average media sentiment score of 1.51 beat Prelude Therapeutics' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rani Therapeutics beats Prelude Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Sinovac Biotech?

Sinovac Biotech (NASDAQ:SVA) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 1,029.03%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Sinovac Biotech's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Rani Therapeutics	N/A	-206.46%	-83.95%

In the previous week, Rani Therapeutics had 3 more articles in the media than Sinovac Biotech. MarketBeat recorded 3 mentions for Rani Therapeutics and 0 mentions for Sinovac Biotech. Rani Therapeutics' average media sentiment score of 1.51 beat Sinovac Biotech's score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
Rani Therapeutics	Very Positive

Rani Therapeutics has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Rani Therapeutics	$1.63M	58.90	-$29.67M	-$0.41	N/A

30.2% of Rani Therapeutics shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sinovac Biotech has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Rani Therapeutics beats Sinovac Biotech on 9 of the 13 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RANI vs. The Competition

Export

Metric	Rani Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$95.88M	$3.71B	$7.04B	$12.94B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.89	9.08	269.98	24.78
Price / Sales	58.90	1,268.95	651.07	108.19
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	2.28	17.65	11.26	6.43
Net Income	-$29.67M	-$13.25M	$3.45B	$347.27M
7 Day Performance	-3.28%	5.21%	3.50%	2.54%
1 Month Performance	12.78%	-1.91%	-0.64%	-1.00%
1 Year Performance	46.78%	60.70%	77.23%	23.33%

Rani Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RANI Rani Therapeutics	3.4461 of 5 stars	$0.78 -2.0%	$8.75 +1,027.6%	+50.0%	$96.13M	$1.63M	N/A	110	Positive News
UPB Upstream Bio	2.3322 of 5 stars	$7.11 +3.4%	$33.17 +366.8%	-54.7%	$386.93M	$3.32M	N/A	38	Upcoming Earnings
CMPX Compass Therapeutics	2.1536 of 5 stars	$2.14 +7.3%	$11.77 +451.3%	-20.4%	$384.49M	$850K	N/A	20	News Coverage Earnings Report Analyst Forecast Analyst Revision Gap Up
RCKT Rocket Pharmaceuticals	2.3404 of 5 stars	$3.50 -1.3%	$8.71 +149.3%	+26.2%	$381.51M	N/A	N/A	240	News Coverage Analyst Downgrade
PRLD Prelude Therapeutics	1.5388 of 5 stars	$4.71 +0.6%	$7.67 +62.8%	+471.4%	$375.90M	$12.14M	N/A	120	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RANI) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rani Therapeutics (RANI) Competitors

RANI vs. UPB, CMPX, RCKT, PRLD, and SVA

How does Rani Therapeutics compare to Upstream Bio?

Summary

How does Rani Therapeutics compare to Compass Therapeutics?

Summary

How does Rani Therapeutics compare to Rocket Pharmaceuticals?

Summary

How does Rani Therapeutics compare to Prelude Therapeutics?

Summary

How does Rani Therapeutics compare to Sinovac Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rani Therapeutics (RANI) Competitors

RANI vs. UPB, CMPX, RCKT, PRLD, and SVA

How does Rani Therapeutics compare to Upstream Bio?

Do insiders & institutionals hold more shares of UPB or RANI?

Do analysts prefer UPB or RANI?

Is UPB or RANI more profitable?

Which has better earnings and valuation, UPB or RANI?

Which has more risk & volatility, UPB or RANI?

Does the media refer more to UPB or RANI?

Summary

How does Rani Therapeutics compare to Compass Therapeutics?

Do analysts rate RANI or CMPX?

Which has stronger valuation and earnings, RANI or CMPX?

Does the media prefer RANI or CMPX?

Do institutionals & insiders believe in RANI or CMPX?

Which has more volatility & risk, RANI or CMPX?

Is RANI or CMPX more profitable?

Summary

How does Rani Therapeutics compare to Rocket Pharmaceuticals?

Does the media prefer RANI or RCKT?

Which has more risk & volatility, RANI or RCKT?

Do analysts recommend RANI or RCKT?

Is RANI or RCKT more profitable?

Which has preferable valuation & earnings, RANI or RCKT?

Do insiders and institutionals believe in RANI or RCKT?

Summary

How does Rani Therapeutics compare to Prelude Therapeutics?

Do analysts recommend RANI or PRLD?

Which has higher valuation & earnings, RANI or PRLD?

Do insiders & institutionals hold more shares of RANI or PRLD?

Is RANI or PRLD more profitable?

Which has more volatility & risk, RANI or PRLD?

Does the media refer more to RANI or PRLD?

Summary

How does Rani Therapeutics compare to Sinovac Biotech?

Do analysts rate SVA or RANI?

Is SVA or RANI more profitable?

Does the media favor SVA or RANI?

Which has higher earnings & valuation, SVA or RANI?

Do insiders and institutionals hold more shares of SVA or RANI?

Which has more volatility & risk, SVA or RANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools